Shares of Spirax-Sarco Engineering plc (LON:SPX – Get Free Report) have been given a consensus rating of “Reduce” by the seven ratings firms that are presently covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is GBX 8,672.50 ($109.46).
Several brokerages recently weighed in on SPX. Shore Capital restated a “sell” rating on shares of Spirax-Sarco Engineering in a research note on Friday, August 30th. Berenberg Bank reissued a “hold” rating and issued a GBX 8,150 ($102.87) price target on shares of Spirax-Sarco Engineering in a report on Wednesday, September 25th.
Spirax-Sarco Engineering Stock Performance
Spirax-Sarco Engineering Company Profile
Spirax-Sarco Engineering plc provides engineered solutions it operates through three segments: Steam Thermal Solutions; Electric Thermal Solutions; and Watson-Marlow Fluid Technology Solutions. The company offers industrial and commercial steam systems, including condensate management, controls, and thermal energy management products and solutions for heating, curing, cooking, drying, cleaning, sterilizing, space heating, humidifying, vacuum packing, and producing hot water; electrical process heating and temperature management solutions, such as industrial heaters and systems, heat tracing, and various component technologies for industrial processes; and peristaltic and niche pumps and associated fluid path technologies, including tubing, and specialty filling systems and products for single-use applications.
Read More
- Five stocks we like better than Spirax-Sarco Engineering
- Upcoming IPO Stock Lockup Period, Explained
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- What is the Dogs of the Dow Strategy? Overview and Examples
- Texas Instruments: The Old-School Tech Titan Still Delivering
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- GRAIL: Biotech Stock Targeting $100B Cancer Market
Receive News & Ratings for Spirax-Sarco Engineering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spirax-Sarco Engineering and related companies with MarketBeat.com's FREE daily email newsletter.